Digital books

Ebooks - Oncology

abstract-A phase II trial cohort of nivolumab plus ipilimum
abstract-Alliance A071601 Phase II trial of BRAFMEK inhibit
abstract-Adjuvant nivolumab NIVO in resected esophageal or
abstract-Ancestral characterization of the genomic landscap
abstract-Breast Cancer Index BCI and prediction of benefit
abstract-Camrelizumab versus placebo combined with gemcitab
abstract-Crossover and rechallenge with pembrolizumab in re
abstract-Combination of famitinib with camrelizumab plus na
abstract-Dalpiciclib versus placebo plus fulvestrant in HRH
abstract-Depth of response and minimal residual disease sta
abstract-Effect of olutasidenib FT2102 on complete remissio
abstract-EORTC 1709CCTG CE8 A phase III trial of marizomib
abstract-EFFORT EFFicacy Of adavosertib in parp ResisTanc
abstract-ESCORT1st A randomized doubleblind placebocontroll
abstract-Final analysis of overall survival OS and relapsef
abstract-Firstline pembrolizumab pembro in cisplatinineligi
abstract-Hepatic arterial infusion chemotherapy of oxalipla
abstract-Fixedduration FD firstline treatment tx with ibrut
abstract-Inducible Tcell costimulatory ICOS receptor agonis
abstract-Lenvatinib len plus pembrolizumab pembro for patie
abstract-Letermovir prophylaxis and cytomegalovirus reactiv
abstract-Metronomic capecitabine as adjuvant therapy in loc
abstract-Myeloablative versus nonmyeloablative consolidativ
abstract-NeoAEGIS Neoadjuvant trial in Adenocarcinoma of th
abstract-Neoadjuvant talazoparib in patients with germlinee
abstract-Oral maintenance capecitabine versus active monito
abstract-Phase 1 firstinhuman study of irreversible FLT3 in
abstract-Pembrolizumab pembro plus axitinib axi versus suni
abstract-Phase II study of antiEGFR rechallenge therapy wit
abstract-Phase 3 randomized singledose openlabel study to i
abstract-Phase II trial of durvalumab plus tremelimumab wit
abstract-Randomized multicenter trial of 3 weekly cabazitax
abstract-Relatlimab RELA plus nivolumab NIVO versus NIVO in
abstract-Testicular cancer in the cisplatin era Causes of d
abstract-Safety and efficacy of a novel antiCD20CD19 bispec
abstract-The combination of venetoclax lenalidomide and rit
abstract-Updated overall survival OS results from the phase
abstract-Trastuzumab plus endocrine therapy or chemotherapy
slides-A Phase 0 trigger trial of CDK46 plus ERK12 inhibi
abstract-Utility of the 70gene MammaPrint assay for predict
slides-A phase 3 trial with a 2x2 factorial design of abi
slides-Allografting Tackling Disease Bugs and Microbiome
slides-ALK inhibitors for treatment of adultonset neurobl
slides-Barriers to CAR TCell Therapy High Cost and Access
slides-Association of increased intensity of prostatespec
slides-Cabozantinib versus placebo in patients with radio
slides-Clinical Implications of HER2Neu in GI Cancers and
slides-CheckMate 067 65year outcomes in patients pts with
slides-Clinical Role of CAR T Cells in Hematologic Malign
slides-Combination of ponatinib and blinatumomab in Phila
slides-Dalpiciclib versus placebo plus fulvestrant in HRH
slides-Do Our Treatments Drive a New Resistant Mutational
slides-Depth of response and minimal residual disease sta
slides-ECOGACRIN E1411 randomized phase 2 trial of bendam
slides-Efficacy and safety of elranatamab PF06863135 a Bc
slides-Efficacy and safety results from neopembrov study
slides-Evaluation of intratumoral IT SD101 and pembrolizu
slides-ESCORT1st A randomized doubleblind placebocontroll
slides-Final analysis of overall survival OS and relapsef
slides-Expanding Therapeutic Strategies in Second Line an
slides-FineTuning the Diagnosis and Treatment of Recurren
slides-Fiveyear overall survival from the antiPD1 brain c
slides-Firstline 1L nivolumab NIVO plus chemotherapy chem
slides-Fixedduration FD firstline treatment tx with ibrut
slides-Healthrelated qualityoflife HRQoL analysis from th
slides-Impact of mutant IDH mIDH inhibition on DNA hydrox
slides-HER2Neu Therapeutics
slides-Intensive versus minimalist followup in patients t
slides-Maintenance therapy with 5fluoruracilleucovorin 5F
slides-Lifileucel LN144 a cryopreserved autologous tumor
slides-Managing HighRisk Relapsed Multiple Myeloma
slides-Neoadjuvant transarterial infusion chemotherapy wi
slides-Neoadjuvant and adjuvant nivolumab nivo with antiL
slides-Nivolumab NIVO plus ipilimumab IPI or NIVO plus ch
slides-New Opportunities in HighRisk EarlyStage Disease
slides-Novel Strategies for Overcoming Resistance to Immu
slides-Outcome of patients with an ultralow risk 70gene s
slides-Optimal Management of HighRisk Myeloma at Diagnosi
slides-Overview of the Biology of HER2Neu
slides-Pembrolizumab pembro plus axitinib axi versus suni
slides-Pathologic Responses As Predictors of Clinical Ben
slides-Phase 1 study of SHR1701 a bifunctional fusion pro
slides-Personalizing FirstLine Therapy for Every Patient
slides-Phase 3 randomized singledose openlabel study to i
slides-Phase II trial of durvalumab plus tremelimumab wit
slides-Preliminary results of a phase II study of alrizom
slides-Realworld RW treatment tx patterns and outcomes of
slides-Randomized multicenter trial of 3 weekly cabazitax
slides-Safety and efficacy of a novel antiCD20CD19 bispec
slides-Results from VERONICA A randomized phase II study
slides-spanHereditary Nonpolyposis Colorectal Cancerspan
slides-The 1994 National Cancer Institutes strategy to fu
slides-Targeting Common Mutations in Rare CNS Tumors
slides-The TRUSTY study A randomized phase 23 study of tr
slides-The randomized phase II study of FOLFOXIRI plus ce
slides-Treatment for Resectable Pancreatic Cancer
slides-Trastuzumab deruxtecan TDXd DS8201 in patients pts
slides-Treatmentrelated side effects and views about dosa
slides-When Less Is More Maintenance Strategies
slides-Upfront Therapy for Mantle Cell Lymphoma Can We Do
abstract-A phase 3 trial with a 2x2 factorial design of abi
abstract-A randomized phase II study comparing cisplatin an
abstract-Adjuvant capecitabine in locoregionally advanced n
abstract-Cabozantinib versus placebo in patients with radio
abstract-Association of pathological response to neoadjuvan
abstract-CALGB 50801 Alliance PET adapted therapy in bulky
abstract-Carfilzomibbased inductionconsolidation with or wi
abstract-COM701 with or without nivolumab Results of an ong
abstract-Durvalumab improves longterm outcome in TNBC resul
abstract-Deescalated neoadjuvant pertuzumabtrastuzumab with
abstract-ECOGACRIN E1411 randomized phase 2 trial of bendam
abstract-Efficacy and safety of elranatamab PF06863135 a Bc
abstract-Efficacy and safety of tisagenlecleucel Tisacel in
abstract-Final overall survival for the phase III KN177 stu
abstract-Evaluation of intratumoral IT SD101 and pembrolizu
abstract-Firstline 1L nivolumab NIVO plus chemotherapy chem
abstract-First results of a headtohead trial of acalabrutin
abstract-Fiveyear overall survival OS in COLUMBUS A randomi
abstract-Impact of mutant IDH mIDH inhibition on DNA hydrox
abstract-Late relapse of germ cell tumors Detection and tre
abstract-Maintenance vigil immunotherapy in newly diagnosed
abstract-Liposomal irinotecan nalIRI in combination with fl
abstract-Multicenter randomized phase II study of neoadjuva
abstract-Neoadjuvant transarterial infusion chemotherapy wi
abstract-Olaparib in recurrent IDHmutant highgrade glioma O
abstract-Optimal treatment duration of bevacizumab BEV comb
abstract-Overall survival OS with palbociclib PAL fulvestr
abstract-Pembrolizumab pembro in combination with gemcitabi
abstract-Phase II evaluation of the triple combination of P
abstract-Phase 2 trial of gemcitabine cisplatin plus nivolu
abstract-Prospective longitudinal evaluation of microbiome
abstract-Primary results of the phase II CheckRadCD8 trial
abstract-Realworld RW treatment tx patterns and outcomes of
abstract-Subcutaneous daratumumab bortezomib cyclophospham
abstract-Safety and efficacy of a novel antiCD20 chimeric a
abstract-The tumor microenvironment TME and atezolizumab e
abstract-The results of multicenter phase II doubleblind pl
abstract-Trastuzumab deruxtecan TDXd DS8201 in patients pts
abstract-VictoriaA multicentric randomized openlabel phase
abstract-Upfront autologous stem cell transplantation ASCT
slides-A randomized phase III postoperative trial of plat
slides-A prospective validation of the genomic classifier
slides-Adjuvant nivolumab NIVO in resected esophageal or
slides-Association of pathological response to neoadjuvan
slides-Ancestral characterization of the genomic landscap
slides-Breast Cancer Index BCI and prediction of benefit
slides-Camrelizumab versus placebo combined with gemcitab
slides-CD20Directed CAR T
slides-Conundrums in FirstLine Urothelial Carcinoma Is Mo
slides-Combination of famitinib with camrelizumab plus na
slides-Crossover and rechallenge with pembrolizumab in re
slides-Deescalated neoadjuvant pertuzumabtrastuzumab with
slides-Durvalumab improves longterm outcome in TNBC resul
slides-Efficacy and safety of larotrectinib in adult and
slides-Efficacy and safety of aspacytarabine BST236 as a
slides-Efficacy and safety of tisagenlecleucel Tisacel in
slides-Enhanced pathologic tumor response with two cycles
slides-Epidemiology and Genetics of Pancreatic Cancer
slides-Expanding VEGF Blockade Combination Therapeutic Op
slides-Finding FirstLine Chemoimmunotherapy for Gastroeso
slides-FineTuning Intensity in Lymphoma Treatment
slides-First report of the safetytolerability and prelimi
slides-Firstinhuman study of lisaftoclax APG2575 a novel
slides-Hepatic arterial infusion chemotherapy of oxalipla
slides-Going Viral Virus Targeted Immunotherapy
slides-Immunotherapy As Curative Therapy in Advanced Kidn
slides-Inducible Tcell costimulatory ICOS receptor agonis
slides-Informing Clinical Practice LongTerm Updates of Pi
slides-Liposomal irinotecan nalIRI in combination with fl
slides-Leveraging Oral Therapy in Advanced Breast Cancer
slides-Maintenance vigil immunotherapy in newly diagnosed
slides-Metronomic capecitabine as adjuvant therapy in loc
slides-Myeloablative versus nonmyeloablative consolidativ
slides-New Versions of Approved Antileukemia Agents Do Th
slides-Neoantigen Landscape and Tumor Mutational Burden
slides-On Target Optimizing CLL Therapy
slides-Novel Therapies for Pancreatic Cancer
slides-OPTIC primary analysis A doseoptimization study of
slides-Perioperative Treatment of Gastroesophageal Cancer
slides-Pembrolizumab pembro in combination with gemcitabi
slides-Overview of the Biology of HER2Neu
slides-Pembrolizumab pembro plus axitinib axi versus suni
slides-Phase 2 trial of gemcitabine cisplatin plus nivolu
slides-Practical Considerations for the Treatment of Pati
slides-Phase II study of antiEGFR rechallenge therapy wit
slides-Preliminary clinical and biologic results of GB127
slides-Prognostic impact of recurrence score endocrine re
slides-Refining Treatment Options for TripleNegative Brea
slides-Safety and efficacy of a novel antiCD20 chimeric a
slides-Resistant Mechanisms and Combinations Partners Wha
slides-Solidifying CDK46 Inhibitors in Advanced Breast Ca
slides-SubtypeDirected Deescalation
slides-Targeting BCRABL and Beyond
slides-The results of multicenter phase II doubleblind pl
slides-The New Avengers in the Treatment of Prostate Canc
slides-Treatment for Borderline Resectable Pancreatic Can
slides-The tumor microenvironment TME and atezolizumab e
slides-Updated results of a phase 1 firstinhuman study of
slides-Updated overall survival OS results from the phase
slides-VictoriaA multicentric randomized openlabel phase
abstract A Phase 0 trigger trial of CDK46 plus ERK12 inhibi
abstract-A prospective validation of the genomic classifier
abstract-A randomized phase III postoperative trial of plat
abstract-ALK inhibitors for treatment of adultonset neurobl
abstract-Association of increased intensity of prostatespec
abstract-CheckMate 067 65year outcomes in patients pts with
abstract-CANTATA Primary analysis of a global randomized pl
abstract-Clinical activity of systemic VSVIFNNIS oncolytic
abstract-Combination of ponatinib and blinatumomab in Phila
abstract-Daratumumab DARA maintenance or observation OBS af
abstract-Efficacy and safety of larotrectinib in adult and
abstract-Efficacy and safety of aspacytarabine BST236 as a
abstract-Efficacy and safety results from neopembrov study
abstract-Enhanced pathologic tumor response with two cycles
abstract-Evaluating the benefit of adaptive randomization i
abstract-Firstinhuman study of lisaftoclax APG2575 a novel
abstract-First report of the safetytolerability and prelimi
abstract-Fiveyear overall survival from the antiPD1 brain c
abstract-Healthrelated qualityoflife HRQoL analysis from th
abstract-Intensive versus minimalist followup in patients t
abstract-Maintenance therapy with 5fluoruracilleucovorin 5F
abstract-Lifileucel LN144 a cryopreserved autologous tumor
abstract-Mirvetuximab soravtansine a folate receptor alpha
abstract-Neoadjuvant and adjuvant nivolumab nivo with antiL
abstract-Nivolumab NIVO plus ipilimumab IPI or NIVO plus ch
abstract-OPTIC primary analysis A doseoptimization study of
abstract-Outcome of patients with an ultralow risk 70gene s
abstract-Phase 1 study of SHR1701 a bifunctional fusion pro
abstract-Pertuzumab plus trastuzumab PT in patients Pts wit
abstract-Phase 2 results of the ZUMA3 study evaluating KTEX
abstract-Prognostic impact of recurrence score endocrine re
abstract-Preliminary results of a phase II study of alrizom
abstract-Randomized study to investigate FOLFOXIRI plus eit
abstract-Results from VERONICA A randomized phase II study
abstract-The 1994 National Cancer Institutes strategy to fu
abstract-The TRUSTY study A randomized phase 23 study of tr
abstract-The randomized phase II study of FOLFOXIRI plus ce
abstract-Updated phase 1 results of teclistamab a Bcell mat
abstract-Treatmentrelated side effects and views about dosa
abstract-Updated results of a phase 1 firstinhuman study of
slides-A randomized phase II study comparing cisplatin an
slides-A phase II trial cohort of nivolumab plus ipilimum
slides-Adjuvant capecitabine in locoregionally advanced n
slides-Alliance A071601 Phase II trial of BRAFMEK inhibit
slides-Beyond Traditional Therapy for Liver Cancer
slides-CANTATA Primary analysis of a global randomized pl
slides-CALGB 50801 Alliance PET adapted therapy in bulky
slides-Carfilzomibbased inductionconsolidation with or wi
slides-Clinical activity of systemic VSVIFNNIS oncolytic
slides-COM701 with or without nivolumab Results of an ong
slides-Defining HighRisk Myeloma in 2021
slides-Daratumumab DARA maintenance or observation OBS af
slides-Does the Treatment Sequence Matter Resolving the C
slides-Developing Targeted Treatments for IDHMutant Gliom
slides-Effect of olutasidenib FT2102 on complete remissio
slides-EORTC 1709CCTG CE8 A phase III trial of marizomib
slides-EFFORT EFFicacy Of adavosertib in parp ResisTance
slides-Expanding the Landscape of Novel Targets in Recurr
slides-Evaluating the benefit of adaptive randomization i
slides-Final overall survival for the phase III KN177 stu
slides-First results of a headtohead trial of acalabrutin
slides-First Impressions Are Lasting Optimizing Upfront T
slides-Fiveyear overall survival OS in COLUMBUS A randomi
slides-Firstline pembrolizumab pembro in cisplatinineligi
slides-Germline Testing and Somatic Mosaicism
slides-How Much How Long Optimizing Adjuvant Therapy Thro
slides-Lenvatinib len plus pembrolizumab pembro for patie
slides-Induction or Adjuvant Therapy for Nasopharyngeal C
slides-Late relapse of germ cell tumors Detection and tre
slides-Letermovir prophylaxis and cytomegalovirus reactiv
slides-Mirvetuximab soravtansine a folate receptor alpha
slides-Mechanisms and Management of Short and Longterm CA
slides-Multicenter randomized phase II study of neoadjuva
slides-Neoadjuvant talazoparib in patients with germlinee
slides-NeoAEGIS Neoadjuvant trial in Adenocarcinoma of th
slides-Olaparib in recurrent IDHmutant highgrade glioma O
slides-Novel Therapeutic Strategies as the Next Step for
slides-Overall survival OS with palbociclib PAL fulvestr
slides-Optimal treatment duration of bevacizumab BEV comb
slides-Pathologic Responses As Predictors of Clinical Ben
slides-Perioperative Treatment of Gastroesophageal Cancer
slides-Pembrolizumab pembro in combination with gemcitabi
slides-Phase 2 results of the ZUMA3 study evaluating KTEX
slides-Pertuzumab plus trastuzumab PT in patients Pts wit
slides-Phase II evaluation of the triple combination of P
slides-Prospective longitudinal evaluation of microbiome
slides-Primary results of the phase II CheckRadCD8 trial
slides-Reassessment of Drug Evaluation in GBM
slides-Randomized study to investigate FOLFOXIRI plus eit
slides-Relatlimab RELA plus nivolumab NIVO versus NIVO in
slides-Targeted Therapy for RecurrentMetastatic Head and
slides-Steps Toward a BladderIntact Cure for MuscleInvasi
slides-The combination of venetoclax lenalidomide and rit
slides-Testicular cancer in the cisplatin era Causes of d
slides-The Evolving Role of Systemic Therapy in Stage III
slides-Trastuzumab plus endocrine therapy or chemotherapy
slides-Updated phase 1 results of teclistamab a Bcell mat
slides-Understanding Tumor Microenvironment
slides-Utility of the 70gene MammaPrint assay for predict
slides-Upfront autologous stem cell transplantation ASCT